RAZA SAIYED ATIQ 4
4 · Arteris, Inc. · Filed Jun 4, 2026
Research Summary
AI-generated summary of this filing
Arteris (AIP) Director Raza Saiyed Atiq Sells Shares
What Happened
- Raza Saiyed Atiq, a director of Arteris, sold a total of 20,839 shares in open-market transactions on June 3, 2026 for an aggregate of approximately $779,175. The sales were executed in three blocks: 8,332 shares at a weighted avg $37.65 (≈ $313,734), 800 shares at $38.46 (≈ $30,767), and 11,707 shares at $37.13 (≈ $434,674). The sales were made pursuant to a pre-existing 10b5-1 trading plan.
- Separately, on June 2, 2026 he was granted 4,703 restricted stock units (RSUs). Those RSUs vest in full on the earlier of the first anniversary of the grant or immediately before the next annual meeting (subject to continued service) and have no expiration. The grant was based on an average price of $31.89 for the period Apr 21–Jun 2, 2026.
- Also on June 3, 2026, 20,839 shares were transferred to the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust (the reporting person is trustee), shown in the filing as a gift/transfer.
Key Details
- Dates: RSU grant on 2026-06-02; gifts/transfers and open-market sales on 2026-06-03. Filing date: 2026-06-04 (appears timely).
- Sale details and price ranges (per filing footnotes):
- 8,332 shares — weighted avg $37.65 (individual trade prices ranged $37.32–$38.27).
- 800 shares — $38.46 (trades ranged $38.33–$38.63).
- 11,707 shares — $37.13 (trades ranged $36.32–$37.31).
- RSU specifics: 4,703 RSUs granted, vesting on first anniversary or before next annual meeting, grant price basis $31.89 (footnote).
- Transfer to trust: 20,839 shares moved to the Saiyed Atiq Raza & Nandini Saraiya 2012 Revocable Trust; reporting person serves as trustee (footnotes).
- Sales executed under a 10b5-1 trading plan adopted Nov 7, 2025 (footnote).
- Shares owned after the transactions are not specified in the provided filing excerpt.
Context
- Gifts/transfers into a revocable trust are generally estate/holding‑structure moves and do not necessarily indicate a change in the insider’s market view.
- Sales executed under a 10b5-1 plan are prearranged trades and are commonly treated as routine rather than immediate signals of sentiment.
- RSU grants are compensation/retention awards; vesting conditions mean the awarded shares are not immediately free to be sold until vesting occurs.
Insider Transaction Report
Form 4
RAZA SAIYED ATIQ
Director
Transactions
- Award
Common Stock
[F1]2026-06-02+4,703→ 25,542 total - Gift
Common Stock
[F2]2026-06-03−20,839→ 4,703 total - Gift
Common Stock
[F3]2026-06-03+20,839→ 160,839 total(indirect: By Trust) - Sale
Common Stock
[F4][F5]2026-06-03$37.65/sh−8,332$313,734→ 152,507 total(indirect: By Trust) - Sale
Common Stock
[F4][F6]2026-06-03$38.46/sh−800$30,767→ 151,707 total(indirect: By Trust) - Sale
Common Stock
[F4][F7]2026-06-03$37.13/sh−11,707$434,674→ 140,000 total(indirect: By Trust)
Footnotes (7)
- [F1]Includes 4,703 restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the earlier of (i) the first anniversary of the grant date and (ii) immediately before the annual meeting of the Issuer's stockholders following the grant date, subject to the reporting person continuing to provide services to Issuer's Board through such vesting date. The RSUs have no expiration date. This grant of restricted stock was made on June 2, 2026, based on the average trading price of Arteris, Inc. common stock for the period from April 21, 2026 through June 2, 2026, which was $31.89.
- [F2]The shares are transferred to Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust for which the reporting person is the trustee.
- [F3]The shares are held by Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust for which the Reporting Person serves as trustee.
- [F4]Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on November 7, 2025.
- [F5]The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $37.32 to $38.27 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $38.33 to $38.63 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $36.32 to $37.31 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Signature
/s/ Paul Alpern, as Attorney-in-Fact for S. Atiq Raza|2026-06-04